European League Against Rheumatism
Rheumatoid Arthritis 2022
This guideline holds 58 pages.
Summary
Updated EULAR RA recommendations reinforce treat-to-target with DAS28 remission as primary goal. JAK inhibitors now carry updated cardiovascular and malignancy safety considerations. csDMARD monotherapy (MTX) remains first-line; biologics and JAKi added when targets not met after 3–6 months.
How the evidence was graded
Grading system
Class I–II
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- European League Against Rheumatism
- Published
- 2022
- Region
- EU
- Language
- English
- Grading system
- Class I–II
Keywords
- Rheumatoid Arthritis
- MTX
- bDMARD
- JAK inhibitors
- Treat-to-target
- DAS28
